Forte Biosciences Geçmiş Kazanç Performansı

NasdaqCM:FBRX Gelir, gider ve kazançlar (USD Millions )
Tarih	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	-36	17	20
31 Mar 24	-32	12	21
31 Dec 23	-31	11	22
30 Sep 23	-30	10	21
30 Jun 23	-24	8	16
31 Mar 23	-18	9	10
31 Dec 22	-14	8	6
30 Sep 22	-12	8	4
30 Jun 22	-17	8	9
31 Mar 22	-19	8	11
31 Dec 21	-22	8	14
30 Sep 21	-23	7	16
30 Jun 21	-20	6	14
31 Mar 21	-49	5	12
31 Dec 20	-46	4	10
30 Sep 20	-43	3	8
30 Jun 20	-39	2	5
31 Mar 20	-5	2	3
31 Dec 19	-4	1	3

Kaliteli Kazançlar: FBRX şu anda kârlı değil.

Büyüyen Kar Marjı: FBRX şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: FBRX kârlı değildir ve zararlar son 5 yılda yılda 2.4% oranında artmıştır.

Büyüme Hızlandırma: FBRX 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: FBRX kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( -2.3% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: FBRX hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -210.82% ) sahiptir.

Forte Biosciences Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Forte Biosciences, Inc. to Report Q4, 2020 Results on Mar 24, 2021

Forte Biosciences, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Forte Biosciences, Inc. to Report Q2, 2020 Results on Aug 10, 2020

Recent updates

High number of new directors

High number of new directors

New major risk - Market cap size

New major risk - Share price stability

Price target increased by 25% to US$4.38

Forte Biosciences, Inc., Annual General Meeting, Aug 20, 2024

We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

New minor risk - Share price stability

New major risk - Financial position

Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

New major risk - Financial position

High number of new directors

Forte Biosciences Receives Non-Compliance Letter from Nasdaq

Camac Partners Shares Key Facts that Reinforce the Need for Urgent Change in Forte Biosciences’s Boardroom

Forte Biosciences, Inc., Annual General Meeting, Sep 19, 2023

New major risk - Shareholder dilution

Forte Biosciences, Inc appoints David Gryska to the Board of Directors

CEO & Chairman recently bought US$105k worth of stock

High number of new and inexperienced directors

Forte Biosciences, Inc. Announces Dr. Scott Brun to Its Board of Directors

Cable Car Capital Expects Response of Forte Biosciences for its Concerns

Cable Car Capital Waiting for the Response of Forte Biosciences

Cable Car Capital Sends Letter to the Board of Forte Biosciences

Large Forte Biosciences shareholder scolds company board of directors

Camac Partners, LLC Urges the Board to Reverse Course and Return Capital to Shareholders

Camac Partners, LLC Urges the Board to Reverse Course and Return Capital to Shareholders

We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

Forte Biosciences: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Forte Biosciences large shareholders make demands for company's future

Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President

Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President

BML Capital Management Sends an Email to Chairman & CEO of Forte Biosciences

Forte Biosciences, Inc. Appoints Stephen K. Doberstein to its Board

Forte Biosciences, Inc., Annual General Meeting, Jun 01, 2022

High number of new and inexperienced directors

High number of new and inexperienced directors

We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

High number of new and inexperienced directors

President recently sold US$4.3m worth of stock

Price target increased to US$103

Director Thomas Darcy has left the company

Forte Biosciences files for $300M mixed shelf offering

Forecast to breakeven in 2025

Forte Biosciences, Inc. Expects to Report the Topline Results from That Trial in the Third Quarter of 2021

Forte Biosciences, Inc. to Report Q4, 2020 Results on Mar 24, 2021

Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

New 90-day low: US$30.76

Forte Biosciences, Inc.(NasdaqCM:FBRX) dropped from Russell 2000 Dynamic Index

New 90-day low: US$33.73

Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences: FB-401 Potentially Best-In-Class In Atopic Dermatitis

Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Forte Biosciences readies equity offering

Forte Biosciences, Inc. Announces the FDA Has Granted Fast Track Designation to FB-401 for the Treatment of Atopic Dermatitis

Forte Biosciences, Inc. Announces First Patient Dosed in the Clinical Trial of FB-401 for the Treatment of Children and Adults with Atopic Dermatitis

New 90-day high: US$50.69

Forte Biosciences, Inc. to Report Q2, 2020 Results on Aug 10, 2020

Forte Biosciences, Inc.(NasdaqCM:FBRX) dropped from Russell Small Cap Completeness Index

Forte Biosciences, Inc.(NasdaqCM:FBRX) dropped from Russell 3000 Index

Forte Biosciences, Inc.(NasdaqCM:FBRX) dropped from Russell 2500 Growth Index

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin